Brought to you by 
Karus teams up with the Univ. of London on PI3K inhibitors
03 Sep 2014
Executive Summary
Karus Therapeutics (oncology and inflammatory disease start-up) will work with Queen Mary, University of London to develop new phosphoinositide 3-kinase (PI3K) inhibitors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Karus teams up with the Univ. of London on PI3K inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice